Mireille Vankemmelbeke
Principal Scientist Scancell
Mireille Vankemmelbeke obtained her PhD from the University of Sheffield (UK), after graduating (BPharm) from the University of Ghent, Belgium. She completed several postdoctoral positions at the Universities of Sheffield and Nottingham, before joining Professor Durrant’s cancer immunotherapy lab, where she focused on generating cancer-targeting anti-glycan antibodies and Fc-engineering to enhance their functionality. Mireille joined Scancell Ltd. in 2018, where, as Principal Scientist, she currently oversees Scancell’s Glymab pipeline.
Seminars
Thursday 10th December 2026
Refining T Cell Bispecifics by Incorporating Competitive Binding & Affinity Tuning Strategies to Improve Solid Tumour Therapy
10:00 am
- Exploring novel approaches including competitive binding strategies and presaturation with blocking antibodies to improve tumour penetration and widen the therapeutic window
- Multi-effector engagement for enduring tumour control
- Leveraging affinity tuning to exploit differential antigen expression, using lower-affinity binders to selectively target tumours with higher antigen density
